Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



(Incorporated in Hong Kong with limited liability)
(Stock code: 2096)

COMPLETION OF ISSUE OF NEW SHARES UNDER THE 2021 RSU SCHEME

References are made to (i) the announcement of Simcere Pharmaceutical Group Limited (the "Company") dated May 21, 2021 in relation to the adoption of the 2021 RSU Scheme; (ii) the announcement of the Company dated August 27, 2021 with respect to, among others, connected transactions in relation to the proposed grant of RSUs to the Connected Grantees; and (iii) the circular of the Company dated October 12, 2021 with respect to, among others, connected transactions in relation to the proposed grant of RSUs to the Connected Grantees (the "Circular"). Unless otherwise defined herein, capitalised terms used in this announcement shall have the same meaning as those defined in the Circular.

The Board is pleased to announce that the Independent Shareholders have approved the Proposed RSU Grants at the EGM and the Listing Committee of the Stock Exchange has granted the listing of, and permission to deal in, the Underlying Shares. All the conditions precedent to the issue of the Underlying Shares have been satisfied and the Company has, on November 12, 2021, issued a total of 8,712,000 new Shares to the Trustee to hold on trust for the Connected Grantees.

The Underlying Shares represent approximately 0.331% of the total number of Shares in issue as enlarged by the issue and allotment of the Underlying Shares and are issued under the General Mandate.

By order of the Board of
Simcere Pharmaceutical Group Limited
Mr. Ren Jinsheng

Chairman and Chief Executive Officer

Hong Kong, November 12, 2021

As at the date of this announcement, the Board comprises Mr. REN Jinsheng as the Chairman and executive Director, Mr. WAN Yushan and Mr. TANG Renhong as the executive Directors; Mr. ZHAO John Huan as the non-executive Director; and Mr. SONG Ruilin, Mr. WANG Jianguo and Mr. WANG Xinhua as the independent non-executive Directors.